How Cangzhou Is Gaining From Beijing-Tianjin-Hebei Integration
Cangzhou, a coastal city in
Located in southeastern
Since 2023, Cangzhou has signed agreements on 170 projects involving Beijing and
One of the clearest examples is biomedicine.
The industrial shift is also reshaping the city's innovation network. Cangzhou has signed cooperation agreements with universities and research institutes in
Those industrial links are being reinforced by transport and logistics. Cangzhou has opened direct high-speed rail service with
Cangzhou is promoting a cross-regional customs and logistics model under which goods would be declared, inspected and released in Xiong'an before being exported by sea through Huanghua Port. Officials describe the effort as part of Cangzhou's work to support Xiong'an's access to maritime logistics.
Regional integration is also reaching public services. Cangzhou has established 27 Beijing-
Cangzhou also reported gains in environmental protection and tourism. According to local authorities, the city's air quality composite index in 2025 fell by 15.14 percent from 2023, while average PM2.5 concentration dropped by 11.47 percent and the number of good-air days increased by 51. Centralized drinking-water sources met Grade III or better standards, and eight rivers flowing into the sea met water-quality targets.
Tourism has benefited from closer regional links and Cangzhou's cultural resources. Drawing on the
In 2026, Cangzhou plans to sign at least 50 new projects involving Beijing and
View original content to download multimedia:https://www.prnewswire.com/news-releases/how-cangzhou-is-gaining-from-beijing-tianjin-hebei-integration-302812912.html
SOURCE Xinhuanet
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mini PC Brand VZMORE Makes Global Debut at ShowStoppers @ IFA 2026, Bringing Advanced Thermal Innovation to Mini PCs
- Best New Meme Coin to Buy: MemeToro Targets Traders Looking Beyond Traditional Memecoin Hype
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share